证券记录 · 已归档季度
RGEN
Repligen Corporation · Healthcare · Medical - Instruments & Supplies
14被追踪持有人
n/aΔ持有人
8.37M持有股份
$1.05B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 11.91K | $1.59M | n/a | n/a |
| Q2 2026 | 125 | +9 | 40.15M | $5.47B | +16 | −8 |
| Q1 2026 | 120 | -2 | 41.26M | $4.90B | +8 | −11 |
| Q4 2025 | 122 | -3 | 43.70M | $7.16B | +1 | −3 |
| Q3 2025 | 21 | +2 | 26.22M | $3.51B | +3 | −2 |
| Q2 2025 | 17 | +1 | 26.68M | $3.32B | +2 | −1 |
| Q1 2025 | 13 | +1 | 13.27M | $1.69B | +1 | n/a |
| Q4 2024 | 12 | 0 | 12.86M | $1.85B | +1 | −1 |
| Q3 2024 | 11 | -3 | 9.29M | $1.38B | n/a | −3 |
| Q2 2024 | 14 | n/a | 8.37M | $1.05B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 4.61M | n/a | $580.94M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (被动) | 945.16K | n/a | $118.96M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Wellington Management ✦ | 784.07K | n/a | $98.84M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Millennium Management ✦ | 756.12K | n/a | $95.32M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 364.55K | n/a | $45.96M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 315.05K | n/a | $39.71M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 213.10K | n/a | $26.86M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Norges Bank ✦ (被动) | 204.72K | n/a | $25.81M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | PRIMECAP Management ✦ | 54.73K | n/a | $6.90M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 50.00K | n/a | $6.30M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 42.20K | n/a | $5.32M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 17.74K | n/a | $2.24M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 6.37K | n/a | $802,876 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 3.42K | n/a | $431,503 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 436 持有人, 65.14M 股份, $6.86B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 05
Loeillot Olivier
Officer, Director · 4.20K 股 · $798,380
Oct 05
Loeillot Olivier
Officer, Director · 1.33K 股 · $238,274
Sep 24
Loeillot Olivier
Officer, Director · 8.40K 股 · $1.60M
Sep 24
Loeillot Olivier
Officer, Director · 4.54K 股 · $862,980
Sep 21
Loeillot Olivier
Officer, Director · 5.43K 股 · $976,680
Sep 04
Loeillot Olivier
Officer, Director · 3.04K 股 · $503,506
Aug 20
Loeillot Olivier
Officer, Director · 5.43K 股 · $976,680
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Oct 07
SC 13G/A: FMR LLC
Aug 14
SC 13G/A: PRICE T ROWE ASSOCIATES INC /MD/
Jul 31
SC 13G: VANGUARD CAPITAL MANAGEMENT LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据